



September 15, 2010  
FOR IMMEDIATE RELEASE

|||||

## Adimab makes FierceBiotech's "Fierce 15" List for 2010

### *Highlights Most Promising Private Biotechnology Companies*

**Lebanon, NH - September 15, 2010** - Adimab, Inc., a leader in the discovery of fully human antibodies, today announced it was named by FierceBiotech as one of 2010's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of "Fierce 15" companies is available online at [www.fiercebiotech.com](http://www.fiercebiotech.com).

"In little more than a year Adimab has signed up four of the biggest names in biopharma as collaborators: Merck, Pfizer, Novartis and Roche," says John Carroll, editor of FierceBiotech. "All have gone to the Lebanon, NH-based biotech--run by the savvy Dartmouth Professor Tillman Gerngross--in search of a quicker, surer way to get their hands on promising new antibody drug candidates. And the highly focused biotech company expects more--and much, much bigger--deals to follow."

"We very much appreciate the recognition by Fierce Biotech, and realize that we receive this award because the ultimate judges of our technology, our pharma partners, have voted with their feet. Antibody discovery is a mature field, therefore any new technology needs to be demonstrably superior to establish a leadership position in such a short period of time," comments Tillman Gerngross, PhD, co-founder and CEO of Adimab. "Our partnerships are structured to provide unencumbered strategic access to the industry's premier antibody discovery platform, and the award reflects the progress we have made on the business development front in the last year."

#### **About Adimab**

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>

**About FierceBiotech**

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at <http://www.fiercebiotech.com>.